Skip to main
INVA
INVA logo

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. has demonstrated robust financial growth through its acquisition strategy, with Giapreza experiencing a remarkable 33% sales increase from 2023 to 2024, while Xerava has consistently realized annual sales growth exceeding 20% since its acquisition. The company has reported a total of 65% growth in yearly sales for Giapreza since its acquisition in the third quarter of 2022, highlighting the effectiveness of its integration and management of these assets. Notably, the annualized run rates for Giapreza and Xerava have nearly doubled since Innoviva acquired them, underscoring the company's successful track record in enhancing the performance of its strategic healthcare assets.

Bears say

Innoviva Inc. is facing a challenging financial outlook as the company is projected to experience a year-over-year decline in royalties from key products, with Relvar/Breo expected to decline by 8% and Anoro by 4% annually over the next eight years. Additionally, the anticipated loss of exclusivity for Giapreza in 2034 further exacerbates concerns about future earnings, as it hinges on the patent for its method of use. Compounded by the diminishing efficacy of colistin against multi-drug-resistant strains, these factors indicate a significant risk to Innoviva's long-term revenue stability and growth potential.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.